Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Position Cut by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lowered its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,959 shares of the company’s stock after selling 431 shares during the period. Illinois Municipal Retirement Fund’s holdings in Amphastar Pharmaceuticals were worth $778,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of AMPH. Point72 Asia Singapore Pte. Ltd. grew its position in Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the last quarter. Asset Management One Co. Ltd. acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter worth approximately $78,000. KBC Group NV grew its holdings in Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after buying an additional 650 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after buying an additional 301 shares in the last quarter. Finally, Point72 DIFC Ltd increased its position in Amphastar Pharmaceuticals by 85.9% in the 3rd quarter. Point72 DIFC Ltd now owns 3,954 shares of the company’s stock valued at $192,000 after acquiring an additional 1,827 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price target for the company. Piper Sandler downgraded shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $66.00 to $36.00 in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $50.33.

Insider Activity

In related news, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total transaction of $437,700.00. Following the completion of the transaction, the director now owns 30,471 shares of the company’s stock, valued at $1,333,715.67. This trade represents a 24.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Rong Zhou sold 7,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the sale, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $27.52 on Tuesday. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of 9.17, a PEG ratio of 2.19 and a beta of 0.81. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a 12 month low of $26.98 and a 12 month high of $53.96. The stock’s 50 day moving average price is $34.74 and its 200 day moving average price is $42.57.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.